about
Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer.Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activationNatural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry.Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer.Evaluation of Social Support, Quality of Life, and Body Image in Women with Breast Cancer.Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.Anal metastasis from breast cancer: a case report and review of the literature.The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.Selected case from the Arkadi M. Rywlin International Pathology Slide Series: Leiomyomatosis peritonealis disseminata: report of 3 cases with extensive review of the literature.Long-term survival in small cell lung cancer: a case report and review of the literature.Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies.Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.Somatostatin Analog Therapy in Small Cell Lung Cancer.Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.Possible applications of circulating tumor cells in patients with non small cell lung cancer.The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma.Progress and challenges in the treatment of small cell lung cancer.Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis.Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.The evolving landscape in advanced penile cancer.Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.The clinical impact of a cardiologic follow-up in breast cancer survivors: an observational study.Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared.Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
P50
Q33413133-28198E57-786B-4124-848F-6EEA13F3DFB5Q33901255-A0F5CEDF-FF0D-4348-A571-3D42321B5613Q34109952-D97ADD4A-6130-41A8-833D-50B772BD2FCDQ34366379-967CD542-BE41-410E-9AFE-3AD1F6FA3E61Q35767943-863DD845-DD97-400A-A35E-8E0C1520989FQ36387861-50D6544E-1146-4E1A-98A4-6EAC741728FBQ36744957-6957B764-EC3D-44DA-BA2E-2600AB896E04Q37291172-08D76A52-E9DA-46E6-B0F2-8CBEBE4677CEQ37335554-3BD28088-19E0-4A80-90BE-9DE291A183EBQ37688103-45DBA1C9-AF49-4015-BA90-7FA5DA383269Q37795307-9756E681-827C-459F-81AB-58DC792A5637Q37968148-63EB69CC-3B16-400F-9746-DF6002EC9A0BQ37992697-C220D094-6492-42B7-BD35-AE26F296581BQ38054930-7A6CE433-8B1C-43DF-9CCA-5E6EE5453BCBQ38117717-E4B74201-E0D8-470F-A41D-9639AE4483E5Q38203124-078E76D1-FA3A-4F97-87BC-6AC2BC7AFF88Q38206270-072AA569-08CF-419C-BA80-86BA044B17BEQ38222242-63A770EE-EDEF-4F76-B386-E9B62D586D9CQ38222703-593B1D11-F5DC-4BAF-A550-B6EA57CA9676Q38551764-91305E03-ABEE-4164-B374-1423001AC21AQ38699712-9BCCD610-40F3-4CFC-8936-EB13C126D54AQ38805172-AD77BC07-02CE-4692-A182-4B9C36925ED4Q38827364-5F4B8228-6065-433F-80FD-00A56CC19770Q38875351-3FFD035D-0ED4-42C5-85AD-FB5B262014F4Q38910154-40057F49-032A-4EC4-AFB6-DCF5AE1DC61BQ39155556-F12B6AAF-841D-48EE-8325-1235C2C8E02CQ39198062-2A77078F-B5A5-4C38-B978-677BF79A44EFQ39272825-EA912D8F-5A83-477F-A1CD-7E25EB49C5A2Q39411127-32A22DCA-1900-428A-9A20-ACB0AFD3DEB1Q39639547-4C6A3A43-3422-4036-BEC4-DDF766D8E961Q41746316-40EBA165-6CA6-44F7-AF1E-6896415EBAA1Q42358603-15CAA810-9AF7-4F4F-970F-843313F18784Q43641621-2BD9BE7E-95B3-4116-8AAF-6CB2B90B9BD8Q43958676-F1DF97CF-8F68-4C05-91A7-965B64CC7645Q45986050-924BD2E1-5427-4F61-9A80-EA92B7AA91B7Q45993980-D7A1F0F3-8AFD-434C-989E-561883342D76Q47110464-29BBD821-90F1-4840-8ED5-478046D17956Q47134673-CAEAFCBF-3591-4514-900F-9B3FE4BB2552Q48128121-3C697CAC-6DCF-443C-A265-EA8E4C340DBEQ51085238-F3A8564D-3EAB-4A04-8458-B04A8405FC83
P50
description
investigador
@es
researcher
@en
name
M Aieta
@en
M Aieta
@nl
type
label
M Aieta
@en
M Aieta
@nl
prefLabel
M Aieta
@en
M Aieta
@nl
P31
P496
0000-0001-9487-6238